LPA receptor-mediated signaling regulates cell motility and survival to anticancer drug of pancreatic cancer cells under glucose-deprived and hypoxic conditions

Takai, Miwa; Takauchi, Minori; Kuribayashi, Mako; Tsujiuchi, Toshifumi

doi:10.1016/j.bbrc.2023.04.036

Cited by 8 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LPA also induces resistance to cisplatin and X-ray irradiation through LPAR2-induced signalling [137]. Resistance to cisplatin in this tumour type is also potentiated by hypoxia, which increases the expression of both LPAR2 and LPAR3 [138,139].…”

Section: Lpa In Drug and Radiotherapy Resistancementioning

confidence: 99%

The Emerging Role of LPA as an Oncometabolite

Karalis,

Poulogiannis

2024

Cells

View full text Add to dashboard Cite

Lysophosphatidic acid (LPA) is a phospholipid that displays potent signalling activities that are regulated in both an autocrine and paracrine manner. It can be found both extra- and intracellularly, where it interacts with different receptors to activate signalling pathways that regulate a plethora of cellular processes, including mitosis, proliferation and migration. LPA metabolism is complex, and its biosynthesis and catabolism are under tight control to ensure proper LPA levels in the body. In cancer patient specimens, LPA levels are frequently higher compared to those of healthy individuals and often correlate with poor responses and more aggressive disease. Accordingly, LPA, through promoting cancer cell migration and invasion, enhances the metastasis and dissemination of tumour cells. In this review, we summarise the role of LPA in the regulation of critical aspects of tumour biology and further discuss the available pre-clinical and clinical evidence regarding the feasibility and efficacy of targeting LPA metabolism for effective anticancer therapy.

show abstract

Section: Lpa In Drug and Radiotherapy Resistancementioning

confidence: 99%